azd-6244 and Thoracic-Neoplasms

azd-6244 has been researched along with Thoracic-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for azd-6244 and Thoracic-Neoplasms

Article	Year
A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). Anti-cancer drugs, 2012, Volume: 23, Issue:7 In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetinib 75 mg twice daily in a phase I trial and has shown complete response for the past 4 years. This case report raises questions regarding treatment schedule, treatment duration and management of adverse events. Topics: Adult; Antineoplastic Agents; Benzimidazoles; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Thoracic Neoplasms	2012

Article

Year

A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).

Anti-cancer drugs, 2012, Volume: 23, Issue:7

In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetinib 75 mg twice daily in a phase I trial and has shown complete response for the past 4 years. This case report raises questions regarding treatment schedule, treatment duration and management of adverse events.

Topics: Adult; Antineoplastic Agents; Benzimidazoles; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Melanoma; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Thoracic Neoplasms

2012